Executive Roundtable: January 22
Co-sponsored with Harvard-MIT CRS!
Now is the time when you can participate in the future of cell and gene therapy by joining a diverse group of participants and executives, including academics, industry experts, patients, and regulators during this interactive Roundtable. Discover the cutting-edge world of cell and gene therapy at our transformative executive roundtable hosted by DIA and Harvard-MIT CRS. Together, we’ll unravel the potential and address the hurdles of this dynamic frontier in health care.
In an era of groundbreaking innovations, cell and gene therapies offer unprecedented solutions for diseases where traditional approaches fell short. However, these groundbreaking therapies bring unique challenges in their development. Join us to foster dialogue, drive transformative change, and work collaboratively to identify the barriers obstructing progress
This will be a groundbreaking opportunity to participate in an interactive, problem-solving roundtable exercise to create real solutions, and we are grateful to the team at Harvard-MIT Center for Regulatory Science (CRS) for co-hosting this event. – Anna McDermott-Vitak, SVP and Managing Director for DIA Americas
It marks the first phase of a comprehensive plan to address challenges in the cell and gene therapy space from discovery through market approval. We are delighted that the roundtable will be attended by – Peter Marks, MD, PhD, Director of CBER at the FDA
“We are looking forward to using this unique and collaborative format, and excited to join DIA in this effort. Together, we will work toward developing solutions to streamline the regulatory pathway for cell and gene therapies. – Florence Bourgeois, MD, Associate Professor of Pediatrics at Harvard Medical School, Boston Children's Hospital and Co-Director Harvard-MIT CRS
Want to learn more about DIA/Harvard-MIT CRS Accelerating Cell and Gene Therapy Executive Roundtable? You've come to the right site!
Have an account?